ClinicalTrials.gg
RecruitingNCT07039669Updated Nov 18, 2025

Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

A Phase 3 interventional study of 611 and Placebo in Pulmonary Disease, Chronic Obstructive (COPD), sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Recruiting at 4 sites in China. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-11-18.

Primary conditionPulmonary Disease, Chronic ObstructiveRegistry: Lung DiseasesReclassifiedWhy we changed it
Registry
Lung Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Disease, Chronic Obstructive
Why
  1. The study's listed conditions name Pulmonary Disease, Chronic Obstructive, a narrower term within Lung Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (part of 3SBio Inc.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
594
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 108 open to participants now, 125 under way, 15 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.

Planned enrollment
60th of 286
594 · median 155
Started
2025
with 41 others
Phase 3
63 of 404
13 open now
Primary completion
2028-09
later than 101 of 124 live
Registered
334th of 404
by date

Among the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 60th largest by planned enrollment of the 286 interventional ones that give a count, is one of 42 that started in 2025, is one of 63 in phase 3, reaches primary completion later than 101 of the 124 other live ones, and was the 334th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

108 of the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:

103 more — sign in →

All 108 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, or all of them as a file.
02

Study summary

The objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.

Read the detailed description

The maximum study duration was 66 weeks per participants, including a screening period of up to 6 weeks, a 52-week randomized treatment period, and a 8-week follow-up period.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive (COPD)

Browse trials for

04

In context

Pulmonary Disease, Chronic Obstructive Reclassified

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

This study's planned enrollment of 594 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. is the lead sponsor of 59 studies on the registry; 22 are open to participants now.

First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc..

Compared within Pulmonary Disease, Chronic Obstructive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and follow the protocol requirements, and give written prior to participation voluntarily in the study.
  2. Male or female adults ages 40 to 85 years old when signing the informed consent.
  3. Current or former smokers with a smoking history of ≥10 pack-years.
  4. Documented diagnosis of for at least 12 months prior to enrolment
  5. Moderate-to-severe COPD.
  6. Documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbations within 12 months prior to enrolment.
  7. Background triple therapy (ICS + LABA + LAMA) for 3 months prior to randomization with a stable dose of medication for ≥ 1 month prior to randomization; Double therapy (LABA + LAMA) allowed if ICS is .
  8. Female subjects of reproductive age (and their male partners) and male subjects (and their female partners) must use highly effective throughout the study period and for at least 3 months after the last dose. The subjects had no plans to pregnancy, donate sperm or donate egg during the whole study period and for at least 3 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Presence of a known pre-existing, lung condition other than .
  2. A current diagnosis of asthma or history of asthma according to the Global Initiative for Asthma (GINA) guidelines or other accepted guidelines.
  3. Diagnosis of α-1 anti-trypsin deficiency.
  4. Presence of an active disease.
  5. Subjects who have any malignant tumors within 5 years prior to enrollment.
  6. Known, pre-existing other concurrent clinically significant medical conditions that are uncontrolled.
  7. Diagnosed active parasitic infection, suspected or high risk of parasitic infection.
  8. Subjects who have active , or infections as determined by positive results at Screening.
  9. Known with allergic or intolerant to any biological product.
  10. Any reason which, in the opinion of investigator, would prevent the subject from participating in the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
594 participants (estimated)

Study arms

  • Experimental
    611

    611 Q2W, subcutaneous (SC) injection

    Drug: 611

  • Placebo comparator
    placebo

    placebo Q2W, subcutaneous (SC) injection

    Drug: Placebo

Interventions

  • Drug611

    611 subcutaneous (SC) injection

  • DrugPlacebo

    placebo Q2W, subcutaneous (SC) injection

07

What researchers measure

Primary outcomes

  1. Annualized rate of moderate or severe COPD Exacerbations

    Moderate exacerbations were recorded by the Investigator and defined as acute exacerbation of COPD (AECOPD) event that required systemic corticosteroids with/without antibiotics. Severe exacerbations were also recorded by the Investigator and defined as AECOPD event that required hospitalization or observation for \>24 hours in an emergency department/urgent care facility or resulted in death.

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Change from baseline in pre-bronchodilator FEV1 at Week 24

    FEV1 is the Forced expiratory volume in one second at study site

    Time frame: Baseline, Week 24

  2. Time to first Moderate or severe COPD exacerbation

    Moderate exacerbations were recorded by the Investigator and defined as acute exacerbation of COPD (AECOPD) event that required systemic corticosteroids with/without antibiotics. Severe exacerbations were also recorded by the Investigator and defined as AECOPD event that required hospitalization or observation for \>24 hours in an emergency department/urgent care facility or resulted in death.

    Time frame: Baseline to Week 52

  3. Annualized rate of severe COPD Exacerbations

    Severe exacerbations were recorded by the Investigator and defined as AECOPD event that required hospitalization or observation for \>24 hours in an emergency department/urgent care facility or resulted in death.

    Time frame: Baseline to Week 52

  4. Change from baseline in pre-bronchodilator FEV1

    FEV1 is the Forced expiratory volume in one second at study site

    Time frame: Baseline to Week 52

  5. Change from baseline in SGRQ scores

    St. George's Respiratory Questionnaire (SGRQ).The SGRQ is a 50-item self-administered questionnaire designed to measure and quantify health status in adult participants with chronic airflow limitation. Scores by dimension were calculated for 3 domains: symptoms (respiratory symptoms: frequency and severity), activity (activities that cause or are limited by breathlessness) and impacts (social functioning and psychological disturbances due to airway disease). Total score was obtained by summing all positive responses in the questionnaire. The minimum and maximum values were 0 and 100, respectively. Higher scores mean a worse outcome. Baseline was defined as the last available value up to randomization but prior to the first dose of study treatment.

    Time frame: Baseline to Week 52

  6. Percentage of participants with a decrease in SGRQ total score of ≥ 4 points from baseline

    Percentage of participants with a decrease in SGRQ total score of ≥ 4 points from baseline

    Time frame: Baseline to Week 16

  7. Change from baseline in post-bronchodilator FEV1

    FEV1 is the Forced expiratory volume in one second at study site

    Time frame: Baseline to Week 52

  8. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

    An AE was defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was defined as any untoward medical occurrence that: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed or worsened or became serious during TE period (between the first administration of study treatment to the last administration of the study treatment + 14 days).

    Time frame: Up to 60 Weeks

  9. 611 Concentration in Serum

    The concentration of 611 in Serum

    Time frame: Baseline to Week 60

  10. Percentage of Participants With Anti-drug Antibodies and Neutralizing Antibodies

    Immunogenicity assessment will be based on Anti-drug Antibodies (ADAs) response and development of Neutralizing Antibodies (NABs). Percentage is calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-drug antibodies / number of evaluable participants \* 100%

    Time frame: Baseline to Week 60

  11. Change in serum concentrations of Pulmonary and activation-regulated chemokine (PARC)

    Change in serum concentrations of PARC

    Time frame: Baseline to Week 60

  12. Change in serum concentrations of IgE

    Change in serum concentrations of IgE

    Time frame: Baseline to Week 60

08

Study locations

2 of 4 sites recruiting
  • China-Japan Friendship Hospital
    Beijing, Beijing Municipality 100029, China
    Not yet recruiting
    • Ting Yang, Master · Contactdryangting@qq.com · +8613651380809
    • Ting Yang, Master · Principal investigator
    • Ke Huang · Sub investigator
  • Shenzhen People's Hospital
    Shenzhen, Guangdong 518020, China
    Recruiting
    • Rongchang Chen, Master · Contactchenrc@vip.163.com · +8613902273260
    • Rongchang Chen, Master · Principal investigator
    • Dandan Chen, site -sub investigator · Sub investigator
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 212028, China
    Recruiting
    • Xin Yao · Contactxyao1998@126.com · +8618651608881
    • Xin Yao · Principal investigator
    • Wei Song · Sub investigator
  • ZheJiang Provincial People's Hospital
    Hangzhou, Zhejiang 310014, China
    Not yet recruiting
    • Yilan Sun · Contact13858188066@126.com · +8613858188066
    • Yilan Sun · Principal investigator
    • Hongbin Zhou · Sub investigator
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Sep 2028, 38 months after the start.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's planned 38 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 26, 2025
StartActual
Jul 16, 2025
Primary completionEst.
Sep 2028
CompletionEst.
Nov 2028
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07039669
Responsible party
Sponsor
First posted
Jun 26, 2025
Start date
Jul 16, 2025
Primary completion
Sep 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Nov 18, 2025

Study contacts

Qinghong Zhou, Master
Contact
zhouqinghong@3sbio.com
+86 18911301578

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camtarkibart

Start the discussion